Sort
39,280 grants matching “leukemia”
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &
$344,620Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA
SOUTHWEST ONCOLOGY GROUP--OPERATIONS OFFICER
$344,561Cancer Therapy And Research Center · U10 · FY2000 · CA
Project 1: Immune Regulation in HCT
$344,535Robert S Negrin · Stanford University · P01 · FY2023 · CA
Filamin interactions in differentiation, invasion and disease
$344,535David A Calderwood · Yale University · R01 · FY2013 · GM
Filamin interactions in differentiation, invasion and disease
$344,535David A Calderwood · Yale University · R01 · FY2014 · GM
Filamin interactions in differentiation, invasion and disease
$344,535David A Calderwood · Yale University · R01 · FY2016 · GM
Filamin interactions in differentiation, invasion and disease
$344,535David A Calderwood · Yale University · R01 · FY2015 · GM
Project 1: Immune Regulation in HCT
$344,535Robert S Negrin · Stanford University · P01 · FY2021 · CA
Understanding how ZFHX4 drives the glioblastoma tumor propagating cell state
$344,531Milan Girish Chheda · Washington University · R01 · FY2021 · NS
Understanding how ZFHX4 drives the glioblastoma tumor propagating cell state
$344,531Milan Girish Chheda · Washington University · R01 · FY2022 · NS
Project 1: Immune Regulation in HCT
$344,521Robert S Negrin · Stanford University · P01 · FY2020 · CA
Clinical Significance of MHC Haplotypes in HCT
$344,520Effie W Petersdorf · Fred Hutchinson Cancer Research Center · R01 · FY2009 · CA
Clinical Significance of MHC Haplotypes in HCT
$344,520Effie W Petersdorf · Fred Hutchinson Cancer Research Center · R01 · FY2008 · CA
Clinical Significance of MHC Haplotypes in HCT
$344,520Effie W Petersdorf · Fred Hutchinson Cancer Research Center · R01 · FY2010 · CA
Project 1: Immune Regulation in HCT
$344,497Robert S Negrin · Stanford University · P01 · FY2019 · CA
New Therapeutic Targets in AML
$344,492Jay L. Hess · Indiana University Indianapolis · R01 · FY2015 · CA
An Integrative Bioinformatics Platform with Application in Single Cancer Cells
$344,463Lana X Garmire · University Of Hawaii At Manoa · R01 · FY2017 · LM
Bmi-1, a potential therapeutic target in ovarian cancer
$344,461Resham Bhattacharya · Mayo Clinic Rochester · R01 · FY2012 · CA
Drug Development of Ribonucleotide Reductase Inhibitor
$344,450Yun Yen · Beckman Research Institute/City Of Hope · R01 · FY2009 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2013 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2015 · CA
Drug Development of Ribonucleotide Reductase Inhibitor
$344,450Yun Yen · Beckman Research Institute/City Of Hope · R01 · FY2010 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2016 · CA
Understanding how ZFHX4 drives the glioblastoma tumor propagating cell state
$344,441Milan Girish Chheda · Washington University · R01 · FY2020 · NS
Endogenous CNTF receptors and adult, in vivo neurogenesis
$344,432Alexander John Maclennan · University Of Cincinnati · R01 · FY2010 · NS